Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan (D-First)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2011 by Kanto CML Study Group.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Takashi Kumagai, Kanto CML Study Group
ClinicalTrials.gov Identifier:
NCT01464411
First received: September 18, 2011
Last updated: November 2, 2011
Last verified: November 2011